Metabolon Target
Fatty Acids Metabolism Targeted Panel
26 Metabolites
Absolute Quantitation
Rigorous Quality Control
End-to-end Service
Fatty Acids Metabolism
Fatty acids play many physiologically important roles in an organism. They are not only key metabolites of energy storage and production but also the basic building blocks of complex lipids that form cellular membranes. A variety of bioactive forms of fatty acid metabolites, known as lipid mediators, act as local hormones and are involved in many physiological systems and pathological processes (eg, eicosanoids, lysophospholipids, resolvins, protectins, maresins). Dysregulation of fatty acid metabolism has been associated with many diseases.
Metabolomics reveals biological insights otherwise unseen. In a successful metabolomics study, both small molecule discovery and the ability to dig deeper into specific biomarkers of interest can uncover actionable insights that propel new therapeutic developments. Liquid chromatography-mass spectrometry (LC-MS) technology and expertise are required to identify these biomarkers of interest and develop assays that are sensitive enough to explore them fully.
At Metabolon, we understand the crucial role that fatty acids play in disease, and we’ve established best-in-class expertise. This panel focuses on specific fatty acids and their metabolic pathways and can be used to track biomarkers and enhance biological understanding across preclinical and clinical research.
Fatty Acids Metabolism Targeted Panel Details
Swipe left/right to view the full table.
| LLOQ* | |
|---|---|
| Metabolite | Plasma/Serum |
| Myristic Acid (14:0) | 1.00 µg/mL |
| Pentadecanoic Acid (15:0) | 0.600 µg/mL |
| Palmitic Acid (16:0) | 8.00 µg/mL |
| Stearic Acid (18:0) | 4.0 µg/mL |
| Arachidic Acid (20:0) | 1.00 µg/mL |
| Myristoleic Acid (14:1n5) | 0.600 µg/mL |
| Palmitoleic Acid (16:1n7) | 1.00 µg/mL |
| Vaccenic Acid (18:1n7) | 1.00 µg/mL |
| Oleic Acid (18:1n9) | 8.00 µg/mL |
| Cis-11-Eicosaenoic Acid (20:1n9) | 0.600 µg/mL |
| Mead Acid (20:3n9) | 1.00 µg/mL |
| Linoleic Acid (18:2n6) | 8.00 µg/mL |
| Gamma-Linolenic Acid (18:3n6) | 0.600 µg/mL |
| Dihomo-Gamma-Linolenic Acid (20:3n6) | 1.00 µg/mL |
| Arachidonic Acid (20:4n6) | 6.00 µg/mL |
| Adrenic Acid (22:4n6) | 0.600 µg/mL |
| Osbond Acid (22:5n6) | 0.600 µg/mL |
| Cis-11,14-Eicosadienoic Acid (20:2n6) | 1.00 µg/mL |
| Alpha-Linolenic Acid (18:3n3) | 0.600 µg/mL |
| Stearidonic Acid (18:4n3) | 0.600 µg/mL |
| Eicosatetraenoic Acid (ETA) (20:4n3) | 0.600 µg/mL |
| Eicosapentaenoic Acid (EPA) (20:5n3) | 1.00 µg/mL |
| Docosapentaenoic Acid (22:5n3) | 1.00 µg/mL |
| Docosahexaenoic Acid (DHA) (22:6n3) | 2.00 µg/mL |
| Margaric Acid (17:0) | 1.00 µg/mL |
| Cis-13-16-Docosadienoic Acid (22:2n6) | 0.600 µg/mL |
Analysis Method and Instrumentation:
Fatty acids are determined by GC-MS (Agilent 7890A/5975C) as their respective methyl esters after conversion of all free and conjugated fatty acids into methyl esters (FAME Analysis). The Fatty Acids Metabolism Targeted Panel measures the total fatty acid content of 28 fatty acids in a variety of matrices.
| Sample Type and Required Amounts | |
|---|---|
| Sample Type | Sample Requirements |
| Plasma/Serum | ≥ 150 µL |
Others on request
Disclaimer: This method is for Research Use Only and is not to be used for diagnostic purposes. The sample requirements listed are for this specific panel. Additional samples will be required if running multiple panels.
Delivering Absolute Quantification for Research and Biomarker Analysis
Our readily available or custom developed quantitative assays help you achieve your research and biomarker validation objectives with precise and fully validated methods. Our targeted assays and panels cover >1,000 metabolites and lipids across a wide range of biochemical classes, metabolic pathways, and physiological processes, and they can be customized to best fit any application.
Fatty Acids Metabolism Targeted Panel Applications
Nutrition
Cardiovascular Diseases
Diabetes
Cancer
Dysregulated metabolism, especially glucose and biosynthetic pathways, is a hallmark change and is essential for the growth and proliferation of individual cancer cells; indeed, the physiological health of the patient is as much a part of the equation as the tumor. Metabolomics can identify cancer-specific drug targets and broadly assess the patient’s overall metabolic phenotype, addressing key questions regarding who might respond to the therapy and who may be adversely affected by a given treatment. This can give insight into determinants of responders/non-responders and potential factors that can possibly cause adverse events, thereby streamlining the screening process, and aiding in better patient care. Thus, Metabolon’s targeted metabolite assays for amino acids, central carbon, glucose tolerance, fatty acid, and tryptophan/kynurenine ratio can inform on treatment development and position programs for success by providing a functional readout of the patients’ and the tumors’ molecular phenotype in multiple biochemical pathways.
Neuroscience
Big Insights with Metabolon
Cited in over 3,000 publications, we help scientists and manufacturers gain greater insight into their studies through metabolomics. See how our approach can become a successful part of your workflow.
Related Metabolomics Resources
Contact Us
Talk with an expert
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.
Corporate Headquarters
617 Davis Drive, Suite 100
Morrisville, NC 27560
Mailing Address:
P.O. Box 110407
Research Triangle Park, NC 27709
